Cell line · CVCL_0324
Papers48
1 to 20 of 48
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Targeting adaptive EGFR feedback enhances the therapeutic efficacy of RMC-6236 in cholangiocarcinoma. | Exp Hematol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Bridging the gap: a genetically validated avian chorioallantoic membrane platform for investigation of spontaneous circulating tumor cells. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| An epithelial GPR35 isoform supports tumor-associated transcriptional and metabolic phenotypes. | FEBS Lett | 2026 | Its Methods give the RRID and name the line | PubMed | |
| SMYD2 regulates lymph node metastasis derived from intrahepatic cholangiocellular carcinoma through CCR7-dependent chemotaxis. | Sci Rep | 2026 | Its Methods give the RRID and name the line | PubMed | |
| HERV2365 upregulates FGF1 expression by sponging miR-326 to promote the progression of intrahepatic cholangiocarcinoma. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting m6A Reader YTHDF1 Enhances Antitumor Immunity and Potentiates Anti-PD-L1 Efficacy in Intrahepatic Cholangiocarcinoma. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Robust transcriptomic hallmarks targeting intratumor heterogeneity in intrahepatic cholangiocarcinoma. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| MYC-Mediated Functional Manifestation of IDH1 Mutations in Intrahepatic Cholangiocarcinoma Confers Sensitivity to (+)-JQ1. | Int J Biol Sci | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Mutant Isocitrate Dehydrogenase 1 Sensitizes Intrahepatic Cholangiocarcinoma Cells to MDM2 Inhibitors. | Cancer Res Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| FXYD3 Promotes Tumor Progression by Binding With IRF7 to Regulate JAK2/STAT5 Signaling in Intrahepatic Cholangiocarcinoma. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Dysfunction of core clock genes regulates malignant phenotype and gemcitabine sensitivity of cholangiocarcinoma cells. | Anticancer Drugs | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Idarubicin-transarterial chemoembolization combined with gemcitabine plus cisplatin for unresectable intrahepatic cholangiocarcinoma. | World J Gastrointest Oncol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Dual Roles of Canagliflozin on Cholangiocarcinoma Cell Growth and Enhanced Growth Suppression in Combination with FK866. | Int J Mol Sci | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Novel B7-H3 CAR T cells show potent antitumor effects in glioblastoma: a preclinical study. | J Immunother Cancer | 2025 | Its Methods give the RRID and name the line | PubMed | |
| YAP-TEAD inhibition is associated with upregulation of an androgen receptor mediated transcription program providing therapeutic escape. | FEBS Open Bio | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Septin 9 expression regulates 'don't eat me' signals and identifies an immune-epithelial class of intrahepatic cholangiocarcinoma. | Mol Oncol | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Generation of a biliary tract cancer cell line atlas reveals molecular subtypes and therapeutic targets. | 2024 | Cellosaurus cites it | PubMed | ||
| NAPRT Silencing in FH-Deficient Renal Cell Carcinoma Confers Therapeutic Vulnerabilities via NAD+ Depletion. | Mol Cancer Res | 2024 | Its Methods give the RRID and name the line | PubMed | |
| The efficacy of ferroptosis-inducing compounds IKE and RSL3 correlates with the expression of ferroptotic pathway regulators CD71 and SLC7A11 in biliary tract cancer cells. | PLoS One | 2024 | Its Methods give the RRID and name the line | PubMed | |
| UBA3 promotes the occurrence and metastasis of intrahepatic cholangiocarcinoma through MAPK signaling pathway. | Acta Biochim Biophys Sin (Shanghai) | 2024 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0324/papers